ArticleClinical rheumatology2025

Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases.

Patricia Ortiz-Fernández et al.PubMed ↗Publisher ↗

No numbers read from the abstract.